Search Results

Terns Pharmaceuticals will advance TERN-601 into Phase II after early-stage data showed the oral therapy led to weight loss of 4.9%, comparable with weight loss pills Lilly and Pfizer are developing, according to analysts.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that members of senior management will be participating in a virtual fireside chat at UBS Obesity Therapeutics Day on Thursday, May 23, 2024 at 1:00 p.m. ET.

Phase I data for TERN-601 suggests Terns’ oral GLP-1 candidate for obesity could be a contender in the market next to big names like Lilly, Pfizer and Roche.

Terns Pharmaceuticals, Inc. announced that members of senior management will be participating in the following upcoming investor conferences in June.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that members of senior management will be participating in a fireside chat at The Citizens JMP Life Sciences Conference 2024 on Tuesday, May 14, 2024 at 1:30 p.m. ET.

Terns Pharmaceuticals, Inc. announced the appointment of Scott Harris as chief development officer effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for TERN-701 for the treatment of chronic myeloid leukemia (CML).

Terns Pharmaceuticals, Inc. announced that preclinical data supporting TERN-501, a highly selective thyroid hormone receptor beta receptor agonist, in combination with a GLP-1 receptor agonist for obesity will be highlighted in a poster presentation at the American Diabetes Association 84th Scientific Sessions, taking place June 21 – 24, 2024 in Orlando, FL.